摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methylnaltrexone, (17S)- | 916045-22-2

中文名称
——
中文别名
——
英文名称
Methylnaltrexone, (17S)-
英文别名
(3S,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one
Methylnaltrexone, (17S)-化学式
CAS
916045-22-2
化学式
C21H26NO4+
mdl
——
分子量
356.4
InChiKey
JVLBPIPGETUEET-UGTAXJHQSA-O
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    66.8
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • NASAL DRUG PRODUCTS AND METHODS OF THEIR USE
    申请人:Lightlake Therapeutics, Inc.
    公开号:US20150258019A1
    公开(公告)日:2015-09-17
    Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.
  • CO-PACKAGED DRUG PRODUCTS
    申请人:Lightlake Therapeutics Inc.
    公开号:US20160008277A1
    公开(公告)日:2016-01-14
    Provided herein are drug products comprising a combination of an opioid receptor agonist and an opioid receptor agonists, including co-packaged drug products comprising an opioid receptor agonist and an opioid receptor antagonist in a delivery device selected from a hand-held auto-injector and a pre-primed nasal delivery device, and methods of prescribing and dispensing same. Methods of lowering opioid overdose risk by providing a combination of an opioid receptor agonist and an opioid receptor agonists, for example by co-packaging an opioid receptor agonist and an opioid receptor antagonist in a delivery device, are also provided.
  • COMPOSITIONS FOR DRUG ADMINISTRATION
    申请人:AEGIS THERAPEUTICS, LLC
    公开号:US20180000942A1
    公开(公告)日:2018-01-04
    The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
  • US9211253B2
    申请人:——
    公开号:US9211253B2
    公开(公告)日:2015-12-15
  • US9468747B2
    申请人:——
    公开号:US9468747B2
    公开(公告)日:2016-10-18
查看更多